<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MAIN OBJECTIVE: To compare the incidence rates of serious cardiovascular events in adult initiators of <z:chebi fb="110" ids="2679">amphetamines</z:chebi> or atomoxetine to rates in non-users </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This was a retrospective cohort study of new <z:chebi fb="110" ids="2679">amphetamines</z:chebi> (n=38,586) or atomoxetine (n=20,995) users </plain></SENT>
<SENT sid="2" pm="."><plain>Each medication user was matched to up to four non-users on age, gender, data source, and state (n=238,183) </plain></SENT>
<SENT sid="3" pm="."><plain>The following events were primary outcomes of interest 1) <z:hpo ids='HP_0001699'>sudden death</z:hpo> or <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, 2) <z:hpo ids='HP_0001297'>stroke</z:hpo>, 3) <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, 4) a composite endpoint of <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Cox proportional hazard regression was used to calculate propensity-adjusted hazard ratios for <z:chebi fb="110" ids="2679">amphetamines</z:chebi> versus matched non-users and atomoxetine versus matched non-users, with intracluster dependence within matched sets accounted for using a robust sandwich estimator </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The propensity-score adjusted hazard ratio for <z:chebi fb="110" ids="2679">amphetamines</z:chebi> use versus non-use was 1.18 (95% CI: 0.55-2.54) for <z:hpo ids='HP_0001699'>sudden death</z:hpo>/<z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, 0.80 (95% CI: 0.44-1.47) for <z:hpo ids='HP_0001297'>stroke</z:hpo>, 0.75 (95% CI: 0.42-1.35) for <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, and 0.78 (95% CI: 0.51-1.19) for <z:hpo ids='HP_0001297'>stroke</z:hpo>/<z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The propensity-score adjusted hazard ratio for atomoxetine use versus non-use was 0.41 (95% CI: 0.10-1.75) for <z:hpo ids='HP_0001699'>sudden death</z:hpo>/<z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, 1.30 (95% CI: 0.52-3.29) for <z:hpo ids='HP_0001297'>stroke</z:hpo>, 0.56 (95% CI: 0.16-2.00) for <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, and 0.92 (95% CI: 0.44-1.92) for <z:hpo ids='HP_0001297'>stroke</z:hpo>/<z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Initiation of <z:chebi fb="110" ids="2679">amphetamines</z:chebi> or atomoxetine was not associated with an elevated risk of serious cardiovascular events </plain></SENT>
<SENT sid="8" pm="."><plain>However, some of the confidence intervals do not exclude modest elevated risks, e.g. for <z:hpo ids='HP_0001699'>sudden death</z:hpo>/<z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
</text></document>